Podcast summary & analysis
Omega-3 Could Be Acting Like a Prebiotic and Improving Inflammation? New Research!
Omega-3 may improve gut microbiome diversity alongside its established cardiovascular and brain benefits
Most people know omega-3 for heart and brain. The newer gut microbiome angle adds another concrete reason to keep intake consistent. The trade-off: this conversation is bracketed by commercial interests — the host (Paleovalley) sells an omega-3 product co-developed with the guest's company (Group Berkham). The underlying science is real; the framing leans toward selling a specific form (phospholipid, herring roe SPMs).
What this episode covers
- Amandine Brochot, a lipidologist heading the Health, Beauty, and Nutrition Division at Group Berkham, joins host Dr.
- Autumn Smith of Paleovalley to discuss omega-3 fatty acids beyond their cardiovascular and brain benefits — specifically their prebiotic-like effects on the gut microbiome, the role of pro-resolving mediators (SPMs) in actively resolving inflammation, and practical dosing for everyday use.
What stands out
- Omega-3 may influence the gut microbiome in addition to cardiovascular and brain health.
- Inflammation is not only reduced; the body may actively resolve inflammation through specialized mediators derived from omega-3.
- The strongest evidence still supports traditional EPA+DHA intake rather than premium omega-3 formulations.
See the broader evidence
1Best-supported action
The single highest-leverage move from this episode, anchored in the strongest evidence the speaker presents.
Get 500 mg combined EPA+DHA per day — through two to three fatty fish meals per week (salmon, sardines, anchovy) or a quality fish oil supplement. This is the dose with the broadest cardiovascular, brain, and emerging gut evidence.
2Where to start
Small low-friction starters covering the main moves from this episode.
- Check how much EPA+DHA you're currently getting from food this week
- Eat one fatty-fish meal this week (salmon, sardines, or anchovy)
- Read the EPA+DHA content on your current supplement label, not just the fish oil total
3Other supported actions
Further actions discussed in this episode, ordered from strongest to weakest evidence. This is one expert's view, the full topic compares and ranks across experts.
- Eat one serving of fatty fish this week, or pull out your current fish oil bottle and check what's printed on it. This is the smallest first step that surfaces where you actually stand today.
- When evaluating any fish oil label, look for 400-500 mg of combined EPA+DHA per 1 g of fish oil. The total milligram count on the front of the bottle (often '1000 mg fish oil') is misleading — the only number that matters is the actual EPA+DHA content.
- If on omega-3 for more than six months, ask your doctor whether an omega-3 index blood test (red blood cell membrane) would be informative. Useful for fine-tuning dose, especially for cardiovascular prevention.
4See the broader evidence
Questions worth asking your doctor
- Given my current cardiovascular risk profile, would 500 mg or 1 g per day combined EPA+DHA make a meaningful difference, or am I already protected by diet?
- Given my current medications (especially blood thinners), is there a dose of omega-3 I should not exceed?
- Given my history of atrial fibrillation or palpitations, is high-dose omega-3 (above 2 g/day) a concern for me?
- Given my elevated triglycerides, would a prescription omega-3 (like icosapent ethyl) be more appropriate than over-the-counter fish oil?
- Given my gut symptoms (bloating, irregular bowels, possible IBD), is there a specific evidence-based role for omega-3 in my situation?
Full doctor prep with ranked questions available in the full topic page
Context
Lipidologist and nutrition scientist leading the Health, Beauty and Nutrition Division at Group Berkham. Brochot focuses on lipid biochemistry, omega-3 metabolism, and specialized pro-resolving mediators (SPMs). Her perspective is informed by industry research and product development, which provides practical insight but also introduces commercial interests that should be considered when evaluating claims about specific omega-3 formulations.
This episode does not prove that phospholipid omega-3 is meaningfully better than triglyceride omega-3 for general use, that pro-resolving mediator supplements from herring roe deliver the same benefits at the doses described as endogenous SPM production, or that omega-3 supplementation will reverse gut dysbiosis or chronic inflammation independent of the rest of diet and lifestyle.
Where people go wrong
- Buying fish oil based on total milligrams of fish oil rather than EPA+DHA content.A '1000 mg fish oil' capsule may contain only 300 mg of actual EPA+DHA, requiring three times the pills to reach the intended dose.
- Paying a significant premium for phospholipid-form omega-3 or pro-resolving mediator supplements based on early-stage and commercially-aligned data.Form-superiority and SPM-supplement claims are not well-established and current evidence does not clearly justify premium pricing over standard triglyceride fish oil.
What to expect over time
- First 6-12 weeksMost healthy adults need 6-12 weeks to see the omega-3 index move into a healthier range from a low baseline.
- Months 3-6Cardiovascular markers (triglycerides especially) and some inflammation markers may shift within this window. Some people may notice digestive changes, though evidence for clinically meaningful gut effects remains early.
- Months 6-24+Long-term cardiovascular protection benefits typically require years of consistent intake to manifest in outcome trials.